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Abstract: Somatic tissue engraftment was studied in BXSB mice treated with mesenchymal 
stem cell transplantation. Hosts were conditioned with nonlethal radiation prior to introducing 
donor cells from major histocompatibility complex-matched green fluorescent protein trans-
genic mice. Transplant protocols differed for route of injection, ie, intravenous (i.v.) versus 
 intraperitoneal (i.p.), and source of mesenchymal stem cells, ie, unfractionated bone marrow cells, 
ex vivo expanded mesenchymal stem cells, or bone chips. Tissue chimerism was determined after 
short (10–12 weeks) or long (62 weeks) posttransplant follow-up by immunohistochemistry for 
green fluorescent protein. Engraftment of endothelial cells was seen in several organs includ-
ing liver sinusoidal cells in i.v. treated mice with ex vivo expanded mesenchymal stem cells 
or with unfractionated bone marrow cells. Periportal engraftment of liver hepatocytes, but not 
engraftment of endothelial cells, was found in mice injected i.p. with bone chips. Engraftment 
of adipocytes was a common denominator in both i.v. and i.p. routes and occurred during early 
phases post-transplant. Disease control was more robust in mice that received both i.v. bone 
marrow and i.p. bone chips compared to mice that received i.v. bone marrow alone. Thus, the 
data support potential use of mesenchymal stem cell transplant for treatment of severe lupus. 
Future studies are needed to optimize transplant conditions and tailor protocols that may in part 
be guided by fat and endothelial biomarkers. Furthermore, the role of liver chimerism in disease 
control and the nature of cellular communication among donor hematopoietic and mesenchymal 
stem cells in a chimeric host merit further investigation.
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Introduction
Mesenchymal stem cell transplantation is rapidly emerging as a treatment modality 
for lupus patients with unremitting disease activity.1,2 Current views emphasize the 
immune modulatory activities of mesenchymal stem cells and the release of potent 
soluble factors even without significant donor engraftment.3 Although this regimen 
appears efficacious, therapeutic sustainability remains unpredictable. While mesen-
chymal stem cell-mediated long-term disease control with tissue tropism, regeneration, 
and self-tolerance is the envisioned endpoint, further investigation is needed to tailor 
transplant protocols for lupus pathogenesis.
Preclinical studies have confirmed the complex interplay between donor mesen-
chymal stem cells and host tissues over time and space. For example, treatment of three 
prototypic lupus models with mesenchymal stem cells produced different outcomes. 
This is an interesting observation as lupus phenotype in all three strains derives from 
immune complex formation against nuclear constituents, and complement activation 
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accounting for chronic inflammation and progressive renal 
failure. However, each strain carries unique genetic factors 
influencing disease immunopathogenesis for breakage of 
tolerance, ie, while MRL/lpr mice show dominance of T cell-
mediated mechanisms, New Zealand black/New Zealand 
white mice show B cell-mediated mechanisms, and BXSB 
mice show monocyte/dendritic cell-mediated mechanisms. 
So far, based on few preclinical reports, MRL/lpr mice 
respond robustly to a single intravenous (i.v.) infusion of ex 
vivo expanded allogeneic bone marrow mesenchymal stem 
cells,2 but New Zealand black/New Zealand white mice fail 
to improve after repeated intraperitoneal (i.p.) injections 
of similar cells.4 The approach in this study using BXSB 
mice was based on the i.p. introduction of mesenchymal 
stem cells in the form of bone chips. Previous experience 
showed that mixed chimerism following gentle condition-
ing induced prolonged disease remission, but only if the 
transplants contained both hematopoietic and mesenchymal 
stem cells.5
The follow-up data on the fate of donor stem cells in vivo 
using paraffin-embedded tissue samples from Jones et al5 
along with additional controls is presented here. The results 
suggest that it is possible to initiate a predictable sequence 
of events resulting in chimerism of the vascular bed and 
somatic tissues.
Materials and methods
Mixed chimerism was established as previously reported.5 
Briefly, male BXSB (10 weeks of age, stock 000740; The 
Jackson Laboratory, Bar Harbor, ME) received nonlethal 
total body irradiation (550 cGy) 4 hours prior to transplant. 
Donors were C57Bl/6 transgenic for green fluorescent 
protein (GFP) (C57BL/6-Tg[CAG-EGFP]1Osb/J; Jackson 
Laboratory). Bone marrow cells were harvested from long 
leg bones by gentle saline flush washed once and injected as 
unfractionated viable cell mixture in normal saline (10 × 106 
per mouse). Remaining bones devoid of marrow were used 
to prepare bone chips; under sterile conditions four pairs 
of femur and four pairs of tibia were ground finely with a 
mortar and pestle, suspended in 4.5 mL saline, and injected 
i.p. in 0.3 cc volumes using a 20 g needle. Treatment arms 
(n = 14–20 mice/group) included: (a) untreated BXSB 
mice, (b) radiation controls, (c) BMT, mice injected i.v. 
with unfractionated bone marrow cells (1 × 107 per mouse), 
(d) MSC, mice injected i.p. with bone chips (equivalent to 
one long bone/mouse), and (e) BMT + MSC, mice trans-
planted both with bone marrow (i.v.) and bone chips (i.p.). 
Paraff in-embedded tissues from surviving mice were 
examined at 62 weeks. Additional groups included 550 cGy 
radiated BXSB mice 10 weeks after BMT (n = 7), 6 weeks 
after i.p. bone chips (ie, MSC, n = 3), 12 weeks after i.v. 
infusion of ex vivo expanded cells from cultured bone chips, 
which were the second passage fibroblastoid CD45- cells 
rapidly growing in Dulbecco’s modified Eagle medium 
with 5% fetal calf serum (n = 3), and BXSB mice treated 
with myeloablative (950 cGy) BMT harvested 10 weeks 
(n = 3) posttransplant.
Automated immunohistochemistry was performed with 
Leica BOND-MAX™ (Leica Microsystems GmbH, Wetzlar, 
Germany), and Novocastra Bond Polymer Refine Detection 
system (Leica Microsystems) was utilized for brown color 
staining with diaminobenzidine chromogen. Deparaffinized 
slides were rinsed and then incubated sequentially with the 
primary antibody, a polyclonal antiGFP antibody (cat Ab290; 
Abcam, Cambridge, MA), secondary antibody, and a polymer 
conjugate. Staining was visualized after incubation with 
diaminobenzidine. Tissue from GFP transgenic mice was the 
positive control. Tissues for negative controls were treated 
similarly, except for omission of the primary antibody.
Results
The following observations were made: (a) injection of i.p. 
mesenchymal cells led to engraftment of hepatocytes that 
appeared to follow engraftment of adipocytes in omentum, 
(b) i.v. injection of bone marrow cells or i.v. injection of 
ex vivo expanded mesenchymal cells resulted in engraftment 
of endothelial cells in multiple organs, and (c) sustained 
long-term disease control required cotreatment with bone 
marrow and bone chips.
After i.p. injection of bone chips, donor engraftment 
appeared to initiate in adipose tissue. This is based on the 
observation that mice examined 6 weeks after i.p. treatment 
revealed a few GFP+ cells exclusively among adipocytes 
harvested serendipitously along with other organs (results 
not shown). As shown in Figures 1 and 2, at 62 weeks post-
transplant, all mice examined showed chimerism in the liver 
and adipose tissue, but the pattern of engraftment differed 
among treatment groups. In the MSC arm, engraftment of 
hepatocytes was periportal and appeared to correlate with 
the extent of tissue inflammation. However, these mice did 
not exhibit engraftment of the remaining organs,  including 
kidney, lung, brain, or spleen. The BMT arm resulted 
in engraftment of endothelial cells in multiple organs 
including liver sinusoidal cells, brain choroid plexus (rich 
network of blood vessels covered by epithelium), as well 
as  vascular endothelial cells in fat tissue, lung, and kidney. 
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Figure 1 Long-term follow-up of mice treated with bone chips as source of mesenchymal stem cells injected intraperitoneally (MSC), unfractionated bone marrow cells 
injected intravenously (BMT), or both (MSC + BMT). Immunohistochemical staining with green fluorescent protein revealed engraftment of the vascular endothelial cells in 
intraabdominal fat tissue in all groups (first row), but staining of perivascular cells (most likely pericytes) was noted in BMT + MSC group. There was clear difference in the 
staining patterns observed in the liver tissue (second row). While BMT exhibited stained sinusoidal endothelial cells, MSC reproducibly showed chimerism among periportal 
hepatocytes. The mice from BMT + MSC group stained for both sinusoidal cells and hepatocytes, periportal as well as scattered parenchymal cells. The third row depicts 
sections of the brain tissue involving choroid plexus of the fourth ventricle (BMT-treated mouse) or choroid plexus of the inferior horn of the lateral ventricle in the region 
of the hippocampus (MSC- or BMT + MSC-treated mice); vascular endothelial cells of the choroid plexus along the abluminal surface and fibrovascular stroma stained positive 
for green fluorescent protein in BMT and BMT + MSC groups, but not the MSC group.
Kidney
BMT MSC BMT + MSC
Lung
Spleen
Figure 2 Long-term follow-up of mice detailed in Figure 1. Donor chimerism identified by green fluorescent protein-positive cells was noted for the vascular endothelial cells 
in the kidney (first row) and lung (second row) parenchyma of BMT-treated mice (unfractionated bone marrow cells injected intravenously). On the other hand, MSC-treated 
mice (bone chips injected intraperitoneally) did not produce any vascular chimerism. The staining in the spleen (third row) corresponds to chimerism among hematopoietic 
cells that was similar between BMT and BMT + MSC (mice transplanted both with bone marrow and bone chips) groups, but was not noted in the MSC group. The latter 
finding correlated with the flow cytometry results on splenocytes.5
Abbreviations: BMT, unfractionated bone marrow cells injected intravenously; MSC, mesenchymal stem cells injected intraperitoneally.
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Figure 3 Short-term follow-up of mice for donor chimerism. The results of BXSB mice conditioned with low dose radiation (550 cgY) and then treated intravenously with 
ex vivo expanded mesenchymal stem cells from cultured bone chips are shown in the first column. The pattern of engraftment in these mice was similar to those treated 
with unfractionated bone marrow cells given after low dose or lethal (950 cgy) radiation. engraftment of donor endothelial cells in the kidney and liver tissues was a common 
finding between these two groups regardless of the levels of hematopoietic chimerism as shown in the spleen tissues (third row).
Abbreviations: BMT, unfractionated bone marrow cells injected intravenously; MSC, mesenchymal stem cells injected intraperitoneally.
Focal  capillary endothelial cell engraftment was seen in 
gut, skin, and striated muscle, but not in pancreas or brain 
parenchyma (data not shown).
Figure 3 summarizes results from additional treatment 
groups involving i.v. injection of mesenchymal stem cells in 
BXSB mice. When these mice were harvested 10–12 weeks 
posttransplant, there was clear evidence for endothelial cell 
engraftment in multiple organs including liver sinusoidal 
cells. However, there was no chimerism among  hepatocytes. 
The pattern of engraftment was similar for the BMT arm. 
Furthermore, the pattern of chimerism was similar for 
BMT following conditioning with high (950 cGy) or low 
(550 cGy) dose radiation, and yielded endothelial cell 
 engraftment similar to that in long-term follow-up group 
(Figures 1 and 2).
As expected, the chimerism in spleen by hematopoietic 
engraftment was maximal in myeloablative BMT (950 cGy) 
and was nondetectible in i.p. injected MSC (Figure 3 and 
Figure 2, respectively). Although nonmyeloablative BMT 
and BMT + MSC groups (Figure 2) had comparable percent-
ages of donor hematopoietic stem cell-derived GFP+ CD45+ 
cells in spleen (data not shown), there were differences in 
the leukocyte populations.5
Discussion
The histopathologic features of chimeric BXSB following 
injection of donor mesenchymal stem cells (MSC arm) alone 
or along with bone marrow cells (BMT arm) were examined. 
The i.p. injection of mesenchymal stem cells was inspired 
by historical papers on MRL/lpr mice, where whole bone 
fragments were implanted under the renal capsule or subcu-
tis to improve donor engraftment and immune competence 
 following myeloablative BMT.6 Introducing donor mesen-
chymal stem cells via bone chips is not common practice, but 
based on these results appears to merit further investigation; 
it is a practical and inexpensive method that requires mini-
mal ex vivo processing. In addition, this technique enables 
transplantation of mesenchymal stem cells in large quantities, 
and is suitable for introducing cells while preserving three-
dimensional scaffolding and natural microenvironment for 
optimal growth and differentiation. Furthermore, the par-
ticulate nature of bone chips may trigger inflammation that 
stimulates communication between donor mesenchymal stem 
cells and host innate immunity. However, this protocol may 
be more important for liver endodermal engraftment than for 
vascular endothelial engraftment and suggests presence of 
donor multipotent adult progenitor cells7 in the transplant.
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The most prominent finding in the MSC group was the 
presence of donor chimerism in hepatocytes derived from 
endodermal stem cells. As noted,3 engraftment correlates with 
inflammatory changes in the liver, and was prominent in mice 
with active lupus. Adipocytes derived from mesodermal stem 
cells were the first to differentiate from i.p. bone chips. This 
may reflect the recent observation that vascular omentum is a 
suitable stem cell niche8 and that the inflammatory milieu can 
facilitate liver regeneration.9 Adipocytes are known potent 
sources of nutrition and vascular endothelial growth factor 
and share a common progenitor with endothelial cells.10 In the 
current study, there were a few capillary structures with GFP+ 
endothelial cells found in the vicinity of adipocytes, even in 
the absence of cotransplanted bone marrow. The topology of 
engraftment suggests the importance of portal circulation for 
the homing of stem cells to liver and that GFP+ pericytes may 
play a role in hematologic dissemination of progenitors.11 
While the impact of donor hepatocytes in disease activity 
is unknown, it may encompass immunomodulation and 
systemic influences on tissue tropism and regeneration by 
soluble factors such as vascular endothelial growth factor. 
Importantly, for cell-based treatments of hepatic tissue,12 
further studies are warranted to explore the use of i.p. bone 
chips for other therapeutic applications, including chronic 
liver diseases.
Immune complex mediated vasculopathy and tissue 
damage are hallmarks of lupus pathogenesis. Endothelial 
engraftment is expected to be crucial for long-term disease 
control.13 The results of the current study provide clear 
evidence that this goal is attainable using cell-based treat-
ment modalities. Multisystem engraftment of endothelial 
cells was found if progenitor cells were introduced by 
i.v. route, but not i.p. route. Although further studies are 
warranted, bone chips appear to harbor not only the bone 
marrow stem cell-derived endothelial cells, as seen in i.v. 
injection of mesenchymal stem cells (Figure 3), but also 
adipose stem cell-derived endothelial cells, as seen in MSC 
arm (Figure 1). Thus, the route of treatment determines the 
extent of endothelial cell chimerism. Furthermore, organ 
specific factors may influence the patterns observed; ie, 
presence of GFP+ sinusoidal cells in the liver and choroid 
plexus in the brain.
In the current model, it was documented that both MSC 
and BMT are necessary to achieve sustained disease control 
with a nonmyeloablative regimen. Alternatively, previous 
reports found that myeloablative transplants with BMT alone 
were able to curtail disease activity.14 Thus, disease control 
can be achieved either through ablation of immune mediated 
tissue damage, ie, by replacing host immune system, or by 
establishing a “steady state” where long-term modulation 
of the immune system can be achieved by donor cells. 
An earlier study suggested that sustained disease control 
can be accomplished in New Zealand black/New Zealand 
white mice after nonmyeloablative transplant of purified 
hematopoietic stem cells.15 Accordingly, it is tempting to 
speculate that BXSB might have additional strain specific 
dependence on donor somatic cells to down regulate tissue 
factors involved in antigenic stimulation and inflammatory 
cascades, and/or for tissue repair and regeneration.
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